Company: AGIO
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001439222-25-000116
Chunk: 179

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 8
Chunk 179
---
, and $1.8 million and $4.8 million for the nine months ended September 30, 2025 and 2024, respectively, in other income, net in the condensed consolidated statements of operations. We hold security deposits from our sublessee of approximately $0.1 million which is recorded within other non-current assets on our condensed consolidated balance sheet.As of September 30, 2025, the future minimum lease payments to be received under the long-term sublease agreements were as follows:(In thousands)Remaining 2025$64 2026387 2027394 202867Total$912 

12

7. Accrued Expenses

Accrued expenses consisted of the following:(In thousands)September 30,2025December 31, 2024Accrued compensation$19,593 $29,935 Accrued research and development costs12,635 10,548 Accrued professional fees1,978 4,316 Accrued other3,011 2,062 Total accrued expenses$37,217 $46,861 

8. Product Revenue

We generate product revenue from sales of PYRUKYND® to a limited number of specialty distributors and specialty pharmacy providers, or collectively, the Customers. These Customers subsequently resell PYRUKYND® to pharmacies or dispense PYRUKYND® directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of PYRUKYND®.The performance obligation related to the sale of PYRUKYND® is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer.Product revenue, net, were as follows: Three Months Ended September 30,Nine Months Ended September 30,(In thousands)2025202420252024Product revenue, net$12,880 $8,964 $34,061 $25,768 Reserves for Variable ConsiderationRevenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to